Anti-signal recognition particle-positive juvenile polymyositis successfully treated with rituximab

Journal of Rheumatology

Volumn 39, Issue 7, 2012, Pages 1483-1485

  Luca, Nadia J C ^a   Atkinson, Adelle ^a   Hawkins, Cynthia ^a   Feldman, Brian M ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI SIGNAL RECOGNITION PARTICLE ANTIBODY; ANTIBODY; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; CALPAIN 3; CARBON DIOXIDE; CREATINE KINASE; DYSFERLIN; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; LEFLUNOMIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHOTREXATE; METHYLPREDNISOLONE; MUSCLE ENZYME; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG;

ABNORMAL LABORATORY RESULT; ABSENCE OF SIDE EFFECTS; B LYMPHOCYTE; CASE REPORT; CD19+ B LYMPHOCYTE; CD20+ T LYMPHOCYTE; CD29+ T LYMPHOCYTE; CHILD; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPHAGIA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; JUVENILE POLYMYOSITIS; LABORATORY TEST; LETTER; LUNG FUNCTION TEST; MEDICAL HISTORY; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYOSITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHYSICAL EXAMINATION; POLYMYOSITIS; PRIORITY JOURNAL; SCHOOL CHILD; T LYMPHOCYTE; TREATMENT RESPONSE; WALKING DIFFICULTY;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; AZATHIOPRINE; CHILD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; MUSCLE, SKELETAL; POLYMYOSITIS; SIGNAL RECOGNITION PARTICLE; TREATMENT OUTCOME;

EID: 84863505086     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.111592     Document Type: Letter

References (17)

1. McCann LJ, Juggins AD, Maillard SM, Wedderburn LR, Davidson JE, Murray KJ, et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland) - Clinical characteristics of children recruited within the first 5 yr. Rheumatology 2006;45:1255-60. (Pubitemid 44542066)
2. Ramanan AV, Feldman BM. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am 2002;28:833-57. (Pubitemid 36008555)
3. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991;70:360-74.
4. Huber AM, Feldman BM, Rennebohm RM, Hicks JE, Lindsley CB, Perez MD, et al. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2004;50:1595-603. (Pubitemid 38608082)
5. Hengstman GJ, ter Laak HJ, Vree Egberts WT, Lundberg IE, Moutsopoulos HM, Vencovsky J, et al. Anti-signal recognition particle autoantibodies: Marker of a necrotising myopathy. Ann Rheum Dis 2006;65:1635-8. (Pubitemid 44799678)
6. Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004;50:209-15. (Pubitemid 38084306)
7. Rouster-Stevens KA, Pachman LM. Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. J Rheumatol 2008;35:927-9. (Pubitemid 351747139)
8. Stringer E, Bohnsack J, Bowyer SL, Griffin TA, Huber AM, Lang B, et al. Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. J Rheumatol 2010;37:1953-61.
9. Levine TD. Rituximab in the treatment of dermatomyositis: An open-label pilot study. Arthritis Rheum 2005;52:601-7. (Pubitemid 40216325)
10. Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006;33:1021-6.
11. Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: An open-label prospective study. J Rheumatol 2007;34:1864-8. (Pubitemid 350067647)
12. Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ. Rituximab for the treatment of juvenile dermatomyositis: A report of four pediatric patients. Arthritis Rheum 2007;56:3107-11. (Pubitemid 47502758)
13. Bader-Meunier B, Decaluwe H, Barnerias C, Gherardi R, Quartier P, Faye A, et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol 2011;38:1436-40.
14. Reed MK, Crowson CS, Oddis CV. Predictors of response to B cell depleting therapy in adult and juvenile myositis [abstract]. Arthritis Rheum 2010;62 Suppl:S573.
15. Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: A case series. Arthritis Care Res 2010;62:1328-34.
16. Benveniste O, Drouot L, Jouen F, Charuel JL, Bloch-Queyrat C, Behin A, et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 2011;63:1961-71.
17. Iwata S, Saito K, Tokunaga M, Yamaoka K, Nawata M, Yukawa S, et al. Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab. J Rheumatol 2011;38:633-41.